9166480

Source:http://linkedlifedata.com/resource/pubmed/id/9166480

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005740, umls-concept:C0008838, umls-concept:C0013216, umls-concept:C0014582, umls-concept:C0027442, umls-concept:C0205088, umls-concept:C0205179, umls-concept:C0205698, umls-concept:C0282460, umls-concept:C0332307, umls-concept:C0684224, umls-concept:C1513186, umls-concept:C1517927
pubmed:issue	3
pubmed:dateCreated	2006-9-25
pubmed:abstractText	This article presents an assessment of the combination of bleomycin, epirubicin, and cisplatin as induction chemotherapy before radiotherapy in the treatment of undifferentiated carcinoma of the nasopharyngeal type in patients with recurrent/metastatic disease (group A), and in previously untreated patients with locoregionally advanced disease (UICC-AJCC 87, N2-3, M0) (group B) in terms of toxicity, antitumoral activity, and therapeutic efficacy.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/9166480-9166473
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9513568
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin
pubmed:status	MEDLINE
pubmed:issn	1081-4442
pubmed:author	pubmed-author:ArmandJ PJP, pubmed-author:AzliNN, pubmed-author:BachoucheAA, pubmed-author:BoussenHH, pubmed-author:CvitkovicEE, pubmed-author:EschwegeFF, pubmed-author:FandiAA, pubmed-author:LianesPP, pubmed-author:RahavGG, pubmed-author:WibaultPP
pubmed:issnType	Print
pubmed:volume	1
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	222-9
pubmed:meshHeading	pubmed-meshheading:9166480-Adolescent, pubmed-meshheading:9166480-Adult, pubmed-meshheading:9166480-Aged, pubmed-meshheading:9166480-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9166480-Bleomycin, pubmed-meshheading:9166480-Carcinoma, pubmed-meshheading:9166480-Child, pubmed-meshheading:9166480-Cisplatin, pubmed-meshheading:9166480-Epirubicin, pubmed-meshheading:9166480-Female, pubmed-meshheading:9166480-Humans, pubmed-meshheading:9166480-Male, pubmed-meshheading:9166480-Middle Aged, pubmed-meshheading:9166480-Nasopharyngeal Neoplasms, pubmed-meshheading:9166480-Neoadjuvant Therapy, pubmed-meshheading:9166480-Neoplasm Metastasis, pubmed-meshheading:9166480-Neoplasm Recurrence, Local, pubmed-meshheading:9166480-Neoplasm Staging, pubmed-meshheading:9166480-Prospective Studies
pubmed:articleTitle	Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
pubmed:affiliation	Institut Gustave Roussy, Savigny Le Temple, France.
pubmed:publicationType	Journal Article, Clinical Trial, Phase II